$1.90
-0.09[-4.52%]
At close: Apr 26
$1.90
0[0.00%]
After Hours: 7:49PM EDT
Esperion Therapeutics
(NASDAQ:ESPR)Esperion Therapeutics Stock (NASDAQ:ESPR), Analyst Ratings, Price Targets, Predictions
Esperion Therapeutics Inc has a consensus price target of $25.14, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from Needham, HC Wainwright & Co., and Needham on April 10, 2024, March 25, 2024, and March 25, 2024. With an average price target of $10.67 between Needham, HC Wainwright & Co., and Needham, there's an implied 461.40% upside for Esperion Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
JP Morgan
B of A Securities
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Esperion Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 321.05% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 742.11% | HC Wainwright & Co. | Joseph Pantginis | → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 321.05% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 742.11% | HC Wainwright & Co. | Joseph Pantginis | $22 → $16 | Maintains | Buy | Get Alert |
| 02/27/2024 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 321.05% | Needham | Serge Belanger | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | — | JP Morgan | Jessica Fye | — | Reinstates | → Neutral | Get Alert |
| 11/13/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 1057.89% | HC Wainwright & Co. | Joseph Pantginis | → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 321.05% | Needham | Serge Belanger | $9 → $8 | Maintains | Buy | Get Alert |
| 10/02/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 373.68% | Needham | Serge Belanger | → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 1057.89% | HC Wainwright & Co. | Joseph Pantginis | → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 373.68% | Needham | Serge Belanger | $10 → $9 | Maintains | Buy | Get Alert |
| 06/26/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 1057.89% | HC Wainwright & Co. | Joseph Pantginis | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 110.53% | B of A Securities | Jason Zemansky | $1.25 → $4 | Upgrade | Underperform → Buy | Get Alert |
| 06/01/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 1057.89% | HC Wainwright & Co. | Joseph Pantginis | → $22 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 426.32% | Needham | Serge Belanger | $12 → $10 | Maintains | Buy | Get Alert |
| 04/18/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 531.58% | Needham | Serge Belanger | → $12 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 531.58% | Needham | Serge Belanger | → $12 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | 57.89% | Morgan Stanley | Jeffrey Hung | $9 → $3 | Maintains | Equal-Weight | Get Alert |
| 03/16/2023 | ESPR | Buy Now | Esperion Therapeutics | $1.90 | -21.05% | B of A Securities | Jason Zemansky | $8 → $1.5 | Downgrade | Neutral → Underperform | Get Alert |
FAQ
What is the target price for Esperion Therapeutics (ESPR)?
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Needham on April 10, 2024. The analyst firm set a price target for $8.00 expecting ESPR to rise to within 12 months (a possible 321.05% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Esperion Therapeutics (ESPR)?
The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by Needham, and Esperion Therapeutics reiterated their buy rating.
When was the last upgrade for Esperion Therapeutics (ESPR)?
The last upgrade for Esperion Therapeutics Inc happened on June 15, 2023 when B of A Securities raised their price target to $4. B of A Securities previously had an underperform for Esperion Therapeutics Inc.
When was the last downgrade for Esperion Therapeutics (ESPR)?
The last downgrade for Esperion Therapeutics Inc happened on March 16, 2023 when B of A Securities changed their price target from $8 to $1.5 for Esperion Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Esperion Therapeutics (ESPR) correct?
While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $0.00 to $8.00. The current price Esperion Therapeutics (ESPR) is trading at is $1.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.